

31 August 2006

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

## Consultation on provisional agreement with Link Pharmaceuticals for listing phenelzine sulphate (Nardil) on the Pharmaceutical Schedule

PHARMAC and Link Pharmaceuticals Ltd have entered into a provisional agreement for the listing of phenelzine sulphate (Nardil) in Section B of the Pharmaceutical Schedule from 1 November 2006. We are now seeking feedback on this proposal.

Key aspects of this proposal are as follows:

- Phenelzine sulphate tablets (Nardil) would be listed in Section B of the Pharmaceutical Schedule from 1 November 2006 at the following price and subsidy (ex-manufacturer, excluding GST):

Pharmaceutical	Brand	Form	Strength	Pack Size	Price and/or subsidy
Phenelzine sulphate	Nardil	Tablet	15 mg	100	\$95.00

It is anticipated that this proposal, if approved by PHARMAC's Board, or Acting Chief Executive under delegated authority, would take effect from 1 November 2006.

If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC by **5:00 pm, 14 September 2006**. All comments submitted by this date will be considered.

Yours sincerely



Geraldine MacGibbon  
Therapeutic Group Manager

P5-2-21 #102975

*Investing in Health*